CCAAPPIITTOOLLOO 66 BIBLIOGRAFIA

1. Silverthorn DU. Il rene. In Fisiologia. Casa Editrice Ambrosiana 2000; cap 18:

518-542.

2. Briggs JP, Kriz W, Schnermann JB. Overview of renal function and structure. In

Greenberg A ed: Primer on kidney diseases. 3rd edition. New York, National

Kidney Foundation 2001; 1: 3-9.

3. Treré D. Le neoplasie. In Le basi patologiche delle malattie, a cura di Cotran,

Kumar, Collins. 6 edizione. Robbins Piccin 2000; cap 8 (vol 1): 299-382. a

4. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic

parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663.

5. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007.

Atlanta, GA: American Cancer Society 2007.

6. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, Ga: American

Cancer Society 2010.

7. Grande E, Inghelmann R, Francisci S, et al. Regional estimates of all cancer

malignancies in Italy. Tumori 2007; 93: 345-351.

8. Linehan WM, Bratslavsky G, Pinto PA, et al. Molecular diagnosis and therapy

of kidney cancer. Annu Rev Med 2010; 61: 329-343.

9. AIRT Working Group. Italian Cancer Figure - Report 2006 - Incidence, mortality

and estimates. Epidemiologia e prevenzione 2006; 30 Suppl 2.

10. AIRT Working Group. Italian Cancer Figure - Report 2007 - Survival.

Epidemiologia e prevenzione 2008; 31 Suppl 1.

11. Mueller-Lisse UG, Mueller-Lisse UL. Imaging of advanced renal cell carcinoma.

World J Urol 2010; 28: 253-261.

12. Wallace AC, Nairn RC. Renal tubular antigens in kidney tumors. Cancer 1972;

29: 977-981.

13. Bennington JL, Beckwith JB. Tumors of the Kidney, Renal Pelvis, and Ureter.

Atlas of Tumor Pathology, 2nd series, fascicle 12. Washington, DC, Armed

Forces Institute of Pathology 1975.

14. Weir JM, Dunn JE Jr. Smoking and mortality: a prospective study. Cancer

1970; 25: 105-112.

15. Kantor AF. Current concepts in the epidemiology and etiology of primary renal

cell carcinoma. J Urol 1977; 117: 415-417.

190

16. La Vecchia C, Negri E, D’Avanzo B, et al. Smoking and renal cell carcinoma.

Cancer Res 1990; 50: 5231-5233.

17. Dhote R, Thiounn N, Debré B, et al. Risk factors for adult renal cell carcinoma.

Urol Clin North Am 2004; 31: 237-247.

18. Klinghoffer Z, Yang B, Kapoor A, et al. Obesity and renal cell carcinoma:

epidemiology, underlying mechanisms and management considerations. Expert

Rev Anticancer Ther 2009; 9: 975-987.

19. Theis RP, Dolwick Grieb SM, Burr D, et al. Smoking, environmental tobacco

smoke, and risk of renal cell cancer: a population-based case-control study.

BMC Cancer 2008; 8: 387.

20. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney

cancer. Nat Rev Urol 2010; 7: 245-257.

21. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and

mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J

Med 2003; 348: 1625-1638.

22. Weng CJ, Chang MY, Chen YC, et al. Long-term online hemodiafiltration does

not reduce the frequency and severity of acquired cystic kidney disease in

hemodialysis patients. Ren Fail 2009; 31: 555-561.

23. Bonsib SM. Renal cystic diseases and renal neoplasms: a mini-review. Clin J

Am Soc Nephrol 2009; 4: 1998-2007.

24. Stewart JH, Vajdic CM, van Leeuwen MT, et al. The pattern of excess cancer in

dialysis and transplantation. Nephrol Dial Transplant 2009; 24: 3225–3231.

25. Zbar B, Lerman M. Inherited carcinomas of the kidney. Adv Cancer Res 1998;

75: 163-201.

26. Deming CL, Harvard BM. Tumors of the kidney. In Campbell MF, Harrison JH,

ed: Urology (vol 2), 3rd edition. Philadelphia: WB Saunders 1970.

27. Dal Bianco M, Fulcoli V. I tumori del rene. In Trattato di Medicina Interna, a

cura di Crepaldi G, Baritussio A. Piccin 2003; cap 253 (vol 3): 3639.

28. Glenn JF. Renal tumors. In Harrison JH, Gittes RF, Perlmutter AD, et al. eds:

Campbell’s Urology, 4th edition. Philadeiphia: WB Saunders 1980.

29. Muto G, Moroni M. I tumori del rene. In Trattato di Chirurgia Oncologica, a cura

di Mazzeo F, Forestieri P. Piccin 2003; cap 67 (vol 3).

30. Barbaric ZL. Principles of Genitourinary Radiology. 2nd edition. New York,

Thieme Medical Publishers 1994; 154.

191

31. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal

cell tumours. J Pathol 1997; 183: 131-133.

32. Lopez-Beltran A, Scarpelli M, Montironi R, et al. 2004 WHO Classification of

the Renal Tumors of the Adults. European Urology 2006; 49: 798–805.

33. Brannon AR, Rathmell WK. Renal cell carcinoma: where will the state-of-the-art

lead us?. Curr Oncol Rep 2010; 12: 193-201.

34. George S, Bukowski RM. Biomarkers in clear cell renal cell carcinoma. Expert

Rev Anticancer Ther 2007; 7: 1737-1747.

35. Eble JN, Sauter G, Epstein JI, et al. WHO: Tumours of the Urinary System and

Male Genital Organs. Lyon: IARC Press 2004.

36. Suzigan S, Lopez-Beltran A, Montironi R, et al. Multilocular cystic renal cell

carcinoma: a report of 45 cases of a kidney tumor of low malignant potential.

Am J Clin Pathol 2006; 125: 217-222.

37. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and

immunohistochemical study of 105 tumors. Mod Pathol 1997; 10 :537-544.

38. Prasad SR, Humphrey PA, Catena JR, et al. Common and Uncommon

Histologic Subtypes of Renal Cell Carcinoma: Imaging Spectrum with

Pathologic Correlation. Radiographics 2006; 26: 1795-1806.

39. Zbar B, Brauch H, Talmadge C, et al. Loss of alleles of loci on the short arm of

chromosome 3 in renal cell carcinoma. Nature 1987; 327: 721–724.

40. Anglard P, Trahan E, Liu S, et al. Molecular and cellular characterization of

human renal cell carcinoma cell lines. Cancer Res 1992; 52: 348-356.

41. Brooks JD, Bova GS, Marshall FF, et al. Tumor suppressor gene allelic loss in

human renal cancers. J Urol 1993; 150: 1278-1283.

42. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease

tumor suppressor gene. Science 1993; 260: 1317-1320.

43. Neumann HP, Zbar B. Renal cysts, renal cancer and von Hippel-Lindau

disease. Kidney Int 1997; 51: 16-26.

44. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor

gene in renal carcinoma. Nat Genet 1994; 7: 85-90.

45. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL)

gene. Its role in renal carcinoma. JAMA 1995; 273: 564-570.

46. Kaelin WG Jr, Maher ER. The VHL tumour-suppressor gene paradigm. Trends

Genet 1998; 14: 423-426.

192

47. Pfaffenroth EC, Linehan WM. Genetic basis for kidney cancer: opportunity for

disease-specific approaches to therapy. Expert Opin Biol Ther 2008; 8: 779-

790.

48. Yao M, Shuin T, Misaki H, et al. Enhanced expression of c-myc and epidermal

growth factor receptor (C-erbB-1) genes in primary human renal cancer.

Cancer Res 1988; 48: 6753-6757.

49. Weidner U, Peter S, Strohmeyer T, et al. Inverse relationship of epidermal

growth factor receptor and HER2/neu gene expression in human renal cell

carcinoma. Cancer Res 1990; 50: 4504-4509.

50. Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated

protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995; 55:

4182-4187.

51. Sidhar SK, Clark J, Gill S, et al. The t(X;1)(p11.2;q21.2) translocation in

papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3

transcription factor gene. Hum Mol Genet 1996; 5: 1333-1338.

52. Haitel A, Wiener HG, Blaschitz U, et al. Biologic behavior of and p53

overexpression in multifocal renal cell carcinoma of clear cell type: an

immunohistochemical study correlating grading, staging, and proliferation

markers. Cancer 1999; 85: 1593-1598.

53. Kugler A, Hemmerlein B, Thelen P, et al. Expression of metalloproteinase 2

and 9 and their inhibitors in renal cell carcinoma. J Urol 1998; 160: 1914-1918.

54. Yoshida MA, Ohyashiki K, Ochi H, et al. Rearrangement of chromosome 3 in

renal cell carcinoma. Cancer Genet Cytogenet 1986; 19: 351-354.

55. Gomella LG, Sargent ER, Wade TP, et al. Expression of transforming growth

factor alpha in normal human adult kidney and enhanced expression of

transforming growth factors alpha and beta 1 in renal cell carcinoma. Cancer

Res 1989; 49: 6972-6975.

56. Sargent ER, Gomella LG, Wade TP, et al. Expression of mRNA for

transforming growth factors-alpha and -beta and secretion of transforming

growth factor-beta by renal cell carcinoma cell lines. Cancer Commun 1989; 1:

317-322.

57. Fisher ER, Horvat B. Comparative ultrastructural study of so-called renal

adenoma and carcinoma. J Urol 1972; 108: 382-386.

58. Colvin RB, Dickersin GR. Pathology of renal tumors. In Skinner DG, DeKemion

JB, eds: Genitourinary Cancer. Philadelphia: WB Saunders 1978; 84.

193

59. Murphy WM. Diseases of the kidney. In Urological Pathology. Philadelphia: WB

Saunders 1989; 409.

60. Kovacs G. Molecular differential pathology of renal cell tumours. Histopathology

1993; 22: 1-8.

61. Rainwater LM, Hosaka Y, Farrow GM, et al. Well differentiated clear cell renal

carcinoma: Significance of nuclear deoxyribonucleic acid patterns studied by

flow cytometry. J Urol 1987; 137: 15-20.

62. Grignon DJ, Ayala AG, el-Naggar A, et al. Renal cell carcinoma. A

clinicopathologic and DNA flow cytometric analysis of 103 cases. Cancer 1989;

64: 2133-2140.

63. Boxer RJ, Waisman J, Lieber MM, et al. Non-metastatic hepatic dysfunction

associated with renal carcinoma. J Urol 1978; 119: 468-471.

64. Bukowski RM. Prognostic factors for survival in metastatic renal cell carcinoma:

update 2008. Cancer 2009; 115: 2273-2281.

65. Banks RE, Craven RA, Harnden P, et al. Key clinical issues in renal cancer: a

challenge for proteomics. World J Urol 2007; 25: 537-556.

66. Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol

2010; 28: 319-327.

67. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th

edition of the AJCC cancer staging manual and the future of TNM. Ann Surg

Oncol 2010; 17: 1471-1474.

68. Kidney. In Edge SB, Byrd DR, Compton CC, et al. eds: AJCC Cancer Staging

Manual. 7th edition. New York, NY: Springer 2010; 479-489.

69. Martinez-Salamanca JI, Huang WC, Millan I, et al. Prognostic Impact of the

2009 UICC/AJCC TNM Staging System for Renal Cell Carcinoma with Venous

Extension. Eur Urol 2010; 13.

70. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic

nomogram predicting recurrence for patients with conventional clear cell renal

cell carcinoma. J Urol 2005; 173: 48-51.

71. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell

carcinoma using an integrated staging system. J Clin Oncol 2001; 19: 1649-

1657.

72. Frank I, Cheville JC, Lohse CM, et al. An outcome prediction model for patients

with clear cell renal cell carcinoma treated with radical nephrectomy based on

194

tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168:

2395-2400.

73. Scoll BJ, Wong YN, Egleston BL, et al. Age, tumor size and relative survival of

patients with localized renal cell carcinoma: a surveillance, epidemiology and

end results analysis. J Urol 2009;181: 506-511.

74. Swierzewski DJ, Swierzewski MJ, Libertino JA. Radical nephrectomy in

patients with renal cell carcinoma with venous, vena caval, and atrial extension.

Am J Surg 1994; 168: 205-209.

75. Medeiros LJ, Gelb AB, Weiss LM. Renal cell carcinoma. Prognostic

significance of morphologic parameters in 121 cases. Cancer 1988; 61: 1639-

1651.

76. Takenawa J, Kaneko Y, Kishishita M, et al. Transcript levels of aquaporin 1 and

carbonic anhydrase IV as predictive indicators for prognosis of renal cell

carcinoma patients after nephrectomy. Int J Cancer 1998; 79: 1-7.

77. Aben KK, Luth TK, Janssen-Heijnen ML, et al. No improvement in renal cell

carcinoma survival: a population-based study in the Netherlands. Eur J Cancer

2008; 44: 1701-1709.

78. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;

163: 408-417.

79. Nosadini R, Fioretto P. L’insufficienza renale cronica. In Trattato di Medicina

Interna, a cura di Crepaldi G, Baritussio A. Piccin 2003; cap 243 (vol 3): 3443-

3467.

80. Swan SK, Keane WF. Clinical evaluation of renal function. In Greenberg A ed:

Primer on kidney diseases. 3rd edition. New York, National Kidney Foundation

2001; 3: 25-28.

81. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum

creatinine. Nephron 1976; 16: 31-41.

82. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate

glomerular filtration rate from serum creatinine: a new prediction equation.

Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:

461-470.

83. Peracchi M, Corbetta S. Disordini del ricambio glicidico. In Malattie del Sistema

Endocrino e del Metabolismo, a cura di Faglia G, 3a edizione. McGraw-Hill

2002; cap 18: 407-447.

195

84. World Health Organisation Department of Noncommunicable Disease

Surveillance Geneva (1999). Definition, Diagnosis and Classification of

Diabetes Mellitus and its Complications. Report of a WHO Consultation.

85. Powers AC. Diabete Mellito. In Principi di Medicina Interna, a cura di Harrison,

15a edizione. McGraw-Hill 2002; cap 333: 2445-2477.

86. Kim HJ, Cho EH, Yoo JH, et al. Proteome analysis of serum from type 2

diabetics with nephropathy. J of Proteome Research 2007; 6: 735-743.

87. American Diabetes Association. Standards of Medical Care in Diabetes-2007.

Diabetes Care 2007; 30 (Suppl 1): S4-S34.

88. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of

diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.

89. Powers AC. Diabetes Mellitus. In Kasper DL, Braunwald E, Fauci AS, et al.

eds: Harrison's Principles of Internal Medicine, 16th edition. New York:

McGraw-Hill Medical Publishing Division 2005; 2152-2180.

90. US Renal Data System. USRDS 2009 annual data report: atlas of chronic

kidney disease and end-stage renal disease in the United States. Bethesda,

MD: National Institutes of Health, National Institute of Diabetes and Digestive

and Kidney Diseases; 2009; 232-241.

91. Seaquist ER, Goetz FC, Rich S, et al. Familial clustering of diabetic kidney

disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J

Med 1989; 320: 1161-1165.

92. Amri K, Freund N, Duong Van Huyen JP, et al. Altered nephrogenesis due to

maternal diabetes is associated with increased expression of IGF-II/mannose-

6-phosphate receptor in the fetal kidney. Diabetes 2001; 50: 1069-1075.

93. Janssen B, Hohenadel D, Brinkkoetter P, et al. Carnosine as a protective factor

in diabetic nephropathy: association with a leucine repeat of the carnosinase

gene CNDP1. Diabetes 2005; 54: 2320-2327.

94. Melville A, Richardson R, Lister-Sharp D, et al. Complications of diabetes: renal

disease and promotion of self-management. Qual Health Care 2000; 9: 257-

263.

95. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in

diabetic nephropathy. Nephron Physiol 2007; 106: 26-31.

96. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in

diabetic glomerulopathy. Curr Diabetes Rev 2008; 4: 39-45.

196

97. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary

wall toward the center of disease: podocyte injury comes of age in diabetic

nephropathy. Diabetes 2005; 54: 1626-1634.

98. Li JJ, Kwak SJ, Jung DS, et al. Podocyte biology in diabetic nephropathy.

Kidney Int Suppl 2007; 106: S36-S42.

99. Doublier S, Salvidio G, Lupia E, et al. Nephrin expression is reduced in human

diabetic nephropathy: evidence for a distinct role for glycated albumin and

angiotensin II. Diabetes 2003; 52: 1023-1030.

100. Hauser PV, Collino F, Bussolati B, et al. Nephrin and endothelial injury. Curr

Opin Nephrol Hypertens 2009; 18: 3-8.

101. Campbell KN, Raij L, Mundel P. Role of angiotensin II in the development of

nephropathy and podocytopathy of diabetes. Curr Diabetes Rev 2011; 7: 3-7.

102. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and

progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-

348.

103. Ozdemir AM, Hopfer U, Erhard P, et al. Processing advanced glycation end

product-modified albumin by the renal proximal tubule and the early

pathogenesis of diabetic nephropathy. Ann N Y Acad Sci 2005; 1043: 625-636.

104. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common

pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25.

105. Rao PV, Lu X, Standley M, et al. Proteomic identification of urinary biomarkers

of diabetic nephropathy. Diabetes Care 2007; 30: 629-637.

106. Crawford J, Cotran RS. Il pancreas. In Le basi patologiche delle malattie, a

cura di Cotran, Kumar, Collins. 6a edizione. Robbins Piccin 2000; cap 20 (vol

2): 1055-1085.

107. Meerwaldt R, Links T, Zeebregts C, et al. The clinical relevance of assessing

advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol

2008; 7: 29.

108. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor

for advanced glycation end products. J Mol Med 2005; 83: 876-886.

109. Nguyen G, Burcklé CA, Sraer JD. Renin/prorenin-receptor biochemistry and

functional significance. Curr Hypertens Rep 2004; 6: 129-132.

110. Ichihara A, Hayashi M, Kaneshiro Y, et al. Inhibition of diabetic nephropathy by

a decoy peptide corresponding to the "handle" region for nonproteolytic

activation of prorenin. J Clin Invest 2004; 114: 1128-1135.

197

111. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney

model in the rat. J Clin Invest 1996; 98: 1063-1068.

112. Del Vecchio L, Sitia S. Aldosterone e danno renale: implicazioni cliniche.

Giornale italiano di nefrologia 2009; 3: 347-354.

113. Miyata K, Rahman M, Shokoji T, et al. Aldosterone stimulates reactive oxygen

species production through activation of NADPH oxidase in rat mesangial cells.

J Am Soc Nephrol 2005; 16: 2906-2912.

114. Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal

inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800.

115. Ritz E, Ogata H, Orth SR. Smoking: a factor promoting onset and progression

of diabetic nephropathy. Diabetes Metab 2000; 26: 54-63.

116. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal

disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983; 32: 64-78.

117. Ritz E. Pathogenesis, Clinical Manifestations, and Natural History of Diabetic

Nephropathy. In Feehally J, Floege J, Johnson RJ eds: Comprehensive Clinical

Nephrology. 3rd edition. Mosby Elsevier 2007; 5: 353-364.

118. Gall MA, Rossing P, Skott P, et al. Prevalence of micro- and macroalbuminuria,

arterial hypertension, retinopathy and large vessel disease in European type 2

(non-insulin-dependent) diabetic patients. Diabetologia 1991; 34: 655-661.

119. Anatomia patologica dell’apparato urinario. In Anatomia patologica clinica, a

cura di Raso M. Piccin Editore Padova 1981; (vol 2): 306.

120. Bloodworth JMB Jr. A re-evaluation of diabetic glomerulosclerosis 50 years

after the discovery of insulin. Human Pathol 1978; 9: 439-453.

121. Viberti G, Keen H. The patterns of proteinuria in diabetes mellitus. Relevance

to pathogenesis and prevention of diabetic nephropathy. Diabetes 1984; 33:

686-692.

122. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic

nephropathy risk: is albumin excretion rate sufficient?. Diabetes 2000; 49:

1399-1408.

123. Penno G, Pucci L, Lucchesi D, et al. Diagnostica di laboratorio: esami su urine.

Gli esami per il diabete. Riv Med Lab-JLM 2002; 1 (vol 3): 44-53.

124. Caramori ML, Mauer M. Diabetic nephropathy. In Greenberg A ed: Primer on

kidney diseases. 3rd edition. New York, National Kidney Foundation 2001; 28:

212-218.

198

125. Rachmani R, Levi Z, Lidar M, et al. Considerations about the threshold value of

microalbuminuria in patients with diabetes mellitus: lessons from an 8-year

follow-up study of 599 patients. Diabetes Res Clin Pract 2000; 49: 187-194.

126. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and

progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347:

797-805.

127. Nakano S, Ogihara M, Tamura C, et al. Reversed circadian blood pressure

rhythm independently predicts endstage renal failure in non-insulin-dependent

diabetes mellitus subjects. J Diabetes Complications 1999; 13: 224-231.

128. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in

patients with type 2 diabetes. N Engl J Med 2002; 346: 1145-1151.

129. Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis,

prevention and treatment. Diabetes Care 2005; 28: 164-176.

130. The Diabetes Control and Complications Trial Research Group. The Effect of

Intensive Treatment of Diabetes on the Development and Progression of Long-

Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med

1993; 329: 977-986.

131. Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for

laboratory analysis in the diagnosis and management of diabetes mellitus.

Clinical Chemistry 2002; 48: 436-472.

132. Reach G. Continuous glucose monitoring and diabetes health outcomes: a

critical appraisal. Diabetes Technol Ther 2008; 10: 69-80.

133. Halford J, Harris C. Determining clinical and psychological benefits and barriers

with continuous glucose monitoring therapy. Diabetes Technol Ther 2010; 12:

201-205.

134. McGarraugh G. The chemistry of commercial continuous glucose monitors. Diabetes Technology & Therapeutics 2009; 11: S17-S24.

135. Keenan DB, Mastrototaro JJ, Voskanyan G, et al. Delays in Minimally Invasive

Continuous Glucose Monitoring Devices: A Review of Current Technology. J of

Diabetes Science and Technology 2009; 5 (vol 3): 1207-1214.

136. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated

average glucose values. Diabetes Care 2008; 31: 1473-1478.

137. [No authors listed]. Executive Summary: standards of medical care in diabetes-

2009. Diabetes Care 2009; 32: S6-S12.

199

138. Mayfield J, Havas S. Self-control: a physician’s guide to blood glucose

monitoring in the management of diabetes. Leawood, KS: American Academy

of Family Physicians 2004.

139. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National

Committee on Prevention, Detection, Evaluation, and Treatment of High Blood

Pressure. Hypertension 2003; 42: 1206-1252.

140. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with

type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting

enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med

2001; 134: 370-379.

141. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus

converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med

2004; 351: 1952-1961.

142. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the

angiotensin-receptor antagonist irbesartan in patients with nephropathy due to

type 2 diabetes. N Engl J Med 2001; 345: 851-860.

143. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and

cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N

Engl J Med 2001; 345: 861-869.

144. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on

the development of diabetic nephropathy in patients with type 2 diabetes. N

Engl J Med 2001; 345: 870-878.

145. Rossing K, Jacobsen P, Pietraszek L, et al. Renoprotective effects of adding

angiotensin II receptor blocker to maximal recommended doses of ACE

inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.

Diabetes Care 2003; 26: 2268-2274.

146. Weinberg AJ, Zappe DH, Ashton M, et al. Safety and tolerability of high-dose

angiotensin receptor blocker therapy in patients with chronic kidney disease: a

pilot study. Am J Nephrol 2004; 24: 340-345.

147. Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of

ultrahigh doses of irbesartan in patients with type 2 diabetes and

microalbuminuria. Kidney Int 2005; 68: 1190-1198.

148. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression

of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116:

288-296.

200

149. Schjoedt KJ, Andersen S, Rossing P, et al. Aldosterone escape during

blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy

is associated with enhanced decline in glomerular filtration rate. Diabetologia

2004; 47: 1936-1939.

150. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney

model in the rat. J Clin Invest 1996; 15: 1063-1068.

151. Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in

patients with diabetic nephropathy. Hypertension 2003; 41: 64-68.

152. Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic

nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75.

153. Solassol J, Jacot W, Lhermitte L, et al. Clinical proteomics and mass

spectrometry profiling for cancer detection. Expert Rev Proteomics 2006; 3:

311-320.

154. Peng J, Gygi SP. Proteomics: the move to mixtures. J Mass Spectrom 2001;

36: 1083-1091.

155. Tolson JP, Flad T, Gnau V, et al. Differential detection of S100A8 in transitional

cell carcinoma of the bladder by pair wise tissue proteomic and

immunohistochemical analysis. Proteomics 2006; 6: 697-708.

156. Wilkins MR, Sanchez JC, Gooley AA, et al. Progress with proteome projects:

why all proteins expressed by a genome should be identified and how to do it.

Biotechnol Genet Eng Rev 1996; 13: 19-50.

157. De Noo ME, Tollenaar RA, Ozalp A, et al. Reliability of human serum protein

profiles generated with C8 magnetic beads assisted MALDI-TOF Mass

Spectrometry. Analytical Chemistry 2005; 77: 7232-7241.

158. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;

422: 198-207.

159. MacNeil JS. Better biomarkers for the diagnostics labyrinth. Genome Technol

2004; 24-33.

160. Nyman TA. The role of mass spectrometry in proteome studies. Biomol Eng

2001; 18: 221-227.

161. International Human Genome Sequencing Consortium. Finishing the

euchromatic sequence of the human genome. Nature 2004; 431: 931-945.

162. Purohit S, Podolsky R, Schatz D, et al. Assessing the utility of SELDI-TOF and

model averaging for serum proteomic biomarker discovery. Proteomics 2006;

6: 6405-6415.

201

163. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker

discovery tool: opportunities and potential limitations. Molecular & Cellular

Proteomics 2004; 3: 367-378.

164. O’Farrell PH. High resolution two-dimensional electrophoresis of proteins.

Journal Biol Chem 1975; 250: 4007-4021.

165. Corti V, Cattaneo A, Bachi A, et al. Identification of grass pollen allergens by

two-dimensional gel electrophoresis and serological screening. Proteomics

2005; 5: 729-736.

166. Ye B, Skates S, Mok SC, et al. Proteomic-based discovery and characterization

of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin

fragments for ovarian cancer in urine. Clinical Cancer Research 2006; 12: 432-

441.

167. Lopez JL. Two-dimensional electrophoresis in proteome expression analysis. J

Chromatogr B Analyt Technol Biomed Life Sci 2007; 849: 190-202.

168. Weissinger EM, Wittke S, Kaiser T, et al. Proteomic patterns established with

capillary electrophoresis and mass spectrometry for diagnostic purposes.

Kidney Int 2004; 65: 2426-2434.

169. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early

detection of cancer. Nature Rev. Cancer 2003; 3: 267-275.

170. Latterich M, Abramovitz M, Leyland-Jones B. Proteomics: New technologies

and clinical applications. Eur J Cancer 2008; 44: 2737-41.

171. Turecek F. Mass spectrometry in coupling with affinity capture-release and

isotope-coded affinity tags for quantitative protein analysis. J Mass Spectrom

2002; 37: 1-14.

172. Baltaci S, Aksoy H, Türkölmez K, et al. Use of percent free prostate-specific

antigen density to improve the specificity for detecting prostate cancer in

patients with normal rectal examinations and intermediate prostate-specific

antigen levels. Urol Int 2003; 70: 36-41.

173. Landers KA, Burger MJ, Tebay MA, et al. Use of multiple biomarkers for a

molecular diagnosis of prostate cancer. Int J Cancer 2005; 114: 950-956.

174. Zhang Z, Barnhill SD, Zhang H, et al. Combination of multiple serum markers

using an artificial neural network to improve specificity in discriminating

malignant from benign pelvic masses. Gynecol Oncol 1999; 73: 56-61.

175. Pan S, Aebersold R, Chen R, et al. Mass Spectrometry Based Targeted Protein

Quantification: Methods and Applications. J Proteome Res 2009; 8: 787-797.

202

176. Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical

research: practical advices. Expert Review of Proteomics 2007 Feb; 4: 51-65.

177. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic

adenocarcinoma using surface-enhanced laser desorption and ionization mass

spectrometry. Clinical Cancer Research 2004; 10: 860-868.

178. Simpkins F, Czechowicz JA, Liotta L, et al. SELDI-TOF mass spectrometry for

cancer biomarker discovery and serum proteomic diagnostics.

Pharmacogenomics 2005; 6: 647-653.

179. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics

for early detection of cancer. Current Opinion in Biotechnology 2004; 15: 24-30.

180. Diamandis EP. Point: proteomic patterns in biological fluids: do they represent

the future of cancer diagnostics?. Clin Chem 2003; 49: 1272-1275.

181. Petricoin III EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum

to identify ovarian cancer. Lancet 2002; 359: 572-575.

182. Conrads TP, Fusaro VA, Ross S, et al. High-resolution serum proteomic

features for ovarian cancer detection. Endocr Relat Cancer 2004; 11: 163-178.

183. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum

proteomic analysis for the detection of early stage ovarian cancer. Cancer

Research 2004; 64: 5882-5890.

184. Lin YW, Lin CY, Lai HC, et al. Plasma proteomic pattern as biomarkers for

ovarian cancer. Int J Gynecol Cancer 2006; 16: 139-146.

185. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities

confer tumor-specific serum peptidome patterns. J Clin Invest 2006; 116: 271-

284.

186. Malik G, Ward MD, Gupta SK, et al. Serum levels of an isoform of

apolipoprotein A-II as a potential marker for prostate cancer. Clinical Cancer

Research 2005; 11: 1073-1085.

187. Boguski MS, McIntosh MW. Biomedical informatics for proteomics. Nature

2003; 422: 233-237.

188. Karsan A, Eigl BJ, Flibotte S, et al. Analytical and preanalytical biases in serum

proteomic pattern analysis for breast cancer diagnosis. Clinical Chemistry

2005; 51: 1525-1528.

189. Papale M, Pedicillo MC, Thatcher BJ, et al. Urine profiling by SELDI-TOF/MS:

Monitoring of the critical steps in sample collection, handling and analysis. J

Chromatogr B Analyt Technol Biomed Life Sciences 2007; 856: 205-213.

203

190. Baumann S, Ceglarek U, Fiedler GM, et al. Standardized approach to

proteome profiling of human serum based on magnetic bead separation and

matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Clinical Chemistry 2005; 51: 973-980.

191. Powell K. Proteomics delivers on promise of cancer biomarkers. Nat Med 2003;

9: 980.

192. Service RF. Public projects gear up to chart the protein landscape. Science

2003; 302: 1316-1318.

193. Schwamborn K, Krieg RC, Grosse J, et al. Serum Proteomic Profiling in

Patients with Bladder Cancer. Eur Urol 2009; 56: 989–997.

194. Cheng AJ, Chen LC, Chien KY, et al. Oral cancer plasma tumor marker

identified with bead-based affinity fractionated proteomic technology. Clin

Chem 2005; 51: 2236-2244.

195. Villanueva J, Philip J, Entenberg D, et al. Serum peptide profiling by magnetic

particle-assisted, automated sample processing and MALDI-TOF mass

spectrometry. Analytical Chemistry 2004; 76: 1560-1570.

196. Ahmed N, Barker G, Oliva K, et al. An approach to remove albumin for the

proteomic analysis of low abundance biomarkers in human serum. Proteomics

2003; 3: 1980-1987.

197. Zhang X, Leung SM, Morris CR, et al. Evaluation of a novel, integrated

approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with

prestructured sample supports, and pattern recognition software for profiling

potential biomarkers in human plasma. J of Biomolecular Techniques 2004; 15:

167-175.

198. Chang JT, Chen LC, Wei SY, et al. Increase diagnostic efficacy by combined

use of fingerprint markers in mass spectrometry--plasma peptidomes from

nasopharyngeal cancer patients for example. Clinical Biochemistry 2006; 39:

1144-1151.

199. De Noo ME, Mertens BJ, Ozalp A, et al. Detection of colorectal cancer using

MALDI-TOF serum protein profiling. European Journal of Cancer 2006; 42:

1068-1076.

200. Thomson JJ. Ray of positive electricity and their application to chemical

analyses. London, Longmans Green and Co 1913.

201. Aston FW. A positive ray spectrograph. Phil Mag 1919; 38: 707-714.

204

202. Aston FW. The mass-spectra of chemical elements. Phil Mag 1920; 39: 611-

625.

203. Aston FW. Mass spectra and atomic weight. J Chem Soc 1921; 119: 677-687.

204. Müller DR, Schindler P, Coulot M, et al. Mass spectrometric characterization of

stathmin isoforms separated by 2D PAGE. J Mass Spectrom 1999; 34: 336-

345.

205. Yates JR. Mass spectrometry and the age of the proteome. J Mass Spectrom

1998; 33: 1-19.

206. Tanaka K, Waki H, Ido Y, et al. Protein and Polymer Analyses up to m/z 100

000 by Laser Ionization Time-of-flight Mass Spectrometry. Rapid Commun

Mass Spectrom 1988; 2: 151-153.

207. Fenn JB, Mann M, Meng CK, et al. Electrospray ionization for mass

spectrometry of large biomolecules. Science 1989; 246: 64-71.

208. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular

masses exceeding 10,000 daltons. Anal Chem 1988; 60; 2299-2301.

209. Hillenkamp F, Karas M, Beavis RC, et al. Matrix-assisted laser

desorption/ionization mass spectrometry of biopolymers. Anal Chem 1991; 63:

1193A-1203A.

210. Katta V, Chow DT, Rohde MF. Applications of in-source fragmentation of

protein ions for direct sequence analysis by delayed extraction MALDI-TOF

mass spectrometry. Anal Chem 1998; 70: 4410-4416.

211. Barber M, Bordoli RS, Sedgwick RD, et al. Fast atom bombardment mass

spectrometry of bleomycin A2 and B2 and their metal complexes. Biochem

Biophys Res Commun 1981; 101: 632-638.

212. Glückmann M, Karas M. The initial ion velocity and its dependence on matrix,

analyte and preparation method in ultraviolet matrix-assisted laser

desorption/ionization. J Mass Spectrom 1999; 34: 467-477.

213. Bakhtiar R, Nelson RW. Electrospray ionization and matrix-assisted laser

desorption ionization mass spectrometry. Emerging technologies in biomedical

sciences. Biochem Pharmacol 2000; 59: 891-905.

214. Jonscher KR, Yates JR. The quadrupole ion trap mass spectrometer—a small

solution to a big challenge. Anal Biochem 1997; 244: 1-15.

215. Marshall A. Fourier transform ion cyclotron resonance detection: principles and

experimental configurations. International J of Mass Spectrometry 2002; 215:

59.

205

216. Shen Y, Smith RD. Advanced nanoscale separations and mass spectrometry

for sensitive high-throughput proteomics. Expert Rev Proteomics 2005; 2: 431-

447.

217. Posthumus MA, Kistemaker PG, Meuzelaar HLC et al. Laser desorption-mass

spectrometry of polar nonvolatile bio-organic molecules. Anal Chem 1978; 50:

985-991.

218. Marvin LF, Roberts MA, Fay LB. Matrix-assisted laser desorption/ionization

time-of-flight mass spectrometry in clinical chemistry. Clinical Chim Acta 2003;

337: 11-21.

219. Wittal RM, Li L. High resolution matrix-assisted laser desorption/ionization in a

linear time-of-flight mass spectrometer. Anal Chem 1995; 67: 1950-1954.

220. Beavis RC, Chait BT. High-accuracy molecular mass determination of proteins

using matrix-assisted laser desorption mass spectrometry. Anal Chem 1990;

62: 1836-1840.

221. Zenobi R, Knochenmuss R. Ion formation in MALDI mass spectrometry. Mass

Spectrom Reviews 1998; 17: 337-366.

222. Karas M, Bahr U, Strupat K, et al. Matrix dependence of metastable

fragmentation of glycoproteins in MALDI TOF mass spectrometry. Anal Chem

1995; 67: 675-679.

223. Cotter RJ. Time-of-flight mass spectrometry: an increasing role in the life

sciences. Biomed Environ Mass Spectrom 1989; 18: 513-532.

224. Katta V, Chow DT, Rohde MF. Application of In-Source fragmentation of

Protein Ions for Direct Sequence Analysis by Delayed Extraction MALDI-TOF

Mass Spectrometry. Anal Chem 1998; 70: 4410-4416.

225. Chaurand P, Luetzenkirchen F, Spengler B. Peptide and protein identification

by matrix-assisted laser desorption ionization (MALDI) and MALDI-post-source

decay time-of-flight mass spectrometry. J Am Soc Mass Spectrom 1999; 10:

91-103.

226. Hoffmann R, Metzger S, Spengler B, et al. Sequencing of peptides

phosphorylated on serines and threonines by post-source decay in matrix-

assisted laser desorption/ionization time-of-flight mass spectrometry. J Mass

Spectrom 1999; 34: 1195-1204.

227. Lee ED, Muck W, Henion JD, et al. On-line capillary zone electrophoresis-ion

spray tandem mass spectrometry for the determination of dynorphins. J

Chromatogr 1988; 458: 313-321.

206

228. Wilm M, Mann M. Analytical properties of the nanoelectrospray ion source.

Anal Chem 1996; 68: 1-8.

229. Wilm M, Sheychenko A, Houthaeve T, et al. Femtomole sequencing of proteins

from polyacrylamide gels by nano-electrospray mass spectrometry. Nature

1996; 379: 466-469.

230. Dooley KC. Tandem mass spectrometry in the clinical chemistry laboratory.

Clinical Biochemistry 2003; 36: 471-481.

231. Yates JR, McCormack AL, Eng J. Mining genomes with MS. Anal Chem 1996;

68: 534-540.

232. Steen H, Mann M. The ABC's (and XYZ's) of peptide sequencing. Nat Rev Mol

Cell Biol 2004; 5: 699-711.

233. Bosso N, Chinello C, Picozzi SCM, et al. Human urine biomarkers of renal cell

carcinoma evaluated by ClinProt. Proteomics Clin Appl 2008; 2: 1036-1046.

234. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240:

1285-1293.

235. Pappin DJ, Hojrup P, Bleasby AJ. Rapid identification of proteins by peptide-

mass fingerprinting. Curr Biol 1993; 3: 327-332.

236. Chinello C, Gianazza E, Zoppis I, et al. Serum biomarkers of renal cell

carcinoma assessed using a protein profiling approach based on clinprot

technique. Urology 2010; 75: 842-847.

237. Gianazza E, Mainini V, Castoldi G, et al. Different expression of fibrinopeptide

A and related fragments in serum of type 1 diabetic patients with nephropathy.

J of Proteomics 2010; 73: 593-601.

238. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes

Care 2004; 27: S79-S83.

239. Cairns DA, Barrett JH, Billingham LJ, et al. Sample size determination in

clinical proteomic profiling experiments using mass spectrometry for class

comparison. Proteomics 2009; 9: 74-86.

240. Magni F, Sarto C, et al. Expanding the proteome two-dimensional gel

electrophoresis reference map of human renal cortex by peptide mass

fingerprinting. Proteomics 2005; 5: 816-825.

241. Pieper R, Gatlin CL, McGrath AM, et al. Characterization of the human urinary

proteome: A method for high-resolution display of urinary proteins on two-

dimensional electrophoresis gels with a yield of nearly 1400 distinct protein

spots. Proteomics 2004; 4: 1159-1174.

207

242. Sarto C, Proserpio V, et al. Insight on renal cell carcinoma proteome. In Sayed

DS, ed: Cancer Proteomics. From Bench to Bedside. Totowa, NJ, Humana

Press 2008; 121-137.

243. Ticozzi-Valerio D, Raimondo F, et al. Differential expression of AQP1 in

microdomain-enriched membranes of renal cell carcinoma. Proteomics Clin

Appl 2007; 1: 588-597.

244. Dallmann K, Junker H, et al. Human agmatinase is diminished in the clear cell

type of renal cell carcinoma. Int J Cancer 2004; 108: 342-347.

245. Von Eggeling F, Junker K, Fiedle W, et al. Mass spectrometry meets chip

technology: A new proteomic tool in cancer research?. Electrophoresis 2001;

22: 2898-2902.

246. Rogers MA, Clarke P, Noble J, et al. Proteomic profiling of urinary proteins in

renal cancer by surface enhanced laser desorption ionization and neural-

network analysis: identification of key issues affecting clinical utility. Cancer

Res 2003; 63: 6971-6983.

247. Hara T, Honda K, et al. Identification of 2 serum biomarkers of renal cell

carcinoma by surface enhanced laser desorption/ ionization mass

spectrometry. J Urol 2005; 174: 1213-1217.

248. Ebert MPA, Niemeyer D, et al. Identification and confirmation of increased

fibrinopeptide A serum protein levels in gastric cancer sera by magnet bead

assisted MALDI-TOF mass spectrometry. J Proteome Res 2006; 5: 2152-2158.

249. Balog CI, Hensbergen PJ, Derks R, et al. Novel Automated Biomarker

Discovery Work Flow for Urinary Peptidomics. Clin Chem 2009; 55: 117-25.

250. Mischak H, Kaiser T, et al. Proteomic analysis for the assessment of diabetic

renal damage in humans. Clin Sci (Lond) 2004; 107: 485-495.

251. Bellei E, Rossi E, et al. Proteomic analysis of early urinary biomarkers of renal

changes in type 2 diabetic patients. Proteomics Clin Appl 2008; 2: 478-491.

252. Jiang H, Guan G, et al. Identification of urinary soluble E-cadherin as a novel

biomarker for diabetic nephropathy. Diabetes Metab Res Rev 2009; 25: 232-

241.

253. Rossing K, Mischak H, et al. Urinary proteomics in diabetes and CKD. J Am

Soc Nephrol 2008; 19: 1283-1290.

254. Timms JF, Arslan-Low E, Gentry-Maharaj A, et al. Preanalytic influence of

sample handling on SELDI-TOF serum protein profiles. Clin Chem 2007; 53:

645-656.

208

255. Hsieh SY, Chen RK, Pan YH, et al. Systematical evaluation of the effects of

sample collection procedures on low-molecular-weight serum/plasma proteome

profiling. Proteomics 2006; 6: 3189-3198.

256. Sundsten T, Eberhardson M, Goransson M, et al. The use of proteomics in

identifying differentially expressed serum proteins in humans with type 2

diabetes. Proteome Sci 2006; 4: 22.

257. Meier M, Kaiser T, Herrmann A, et al. Identification of urinary protein pattern in

type 1 diabetic adolescents with early diabetic nephropathy by a novel

combined proteome analysis. J Diabetes Complicat 2005; 19: 223-232.

258. Snell-Bergeon JK, Maahs DM, Ogden LG, et al. Evaluation of urinary

biomarkers for coronary artery disease, diabetes, and diabetic kidney disease.

Diabetes Technol Ther 2009; 11: 1-9.

259. Albrethsen J, Kaas A, Schonle E, et al. Evaluation of a type 1 diabetes serum

cohort by SELDI-TOF MS protein profiling. Proteomics Clin Appl 2009; 3: 383-

393.

260. Alkjaersig N, Fletcher AP. Catabolism and Excretion of Fibrinopeptide A. Blood

1982; 60: 148-156.

261. Sporn LA, Bunce LA, Francis CW. Cell proliferation on fibrin: modulation by

fibrinopeptide cleavage. Blood 1995; 86:1802-10.

262. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thrombosis

Haemostasis 2005; 3: 1894-1904.

263. Kaizu K, Uriu K, Hashimoto O, et al. Role of intrarenal coagulation and

anticoagulant therapy in the progression of diabetic nephropathy. Nippon Jinzo

Gakkai Shi 1993; 35: 35-42.

264. Herrick S, Blanc-Brude O, Gray A, et al. Fibrinogen. International J Biochem

Cell Biology 1999; 31: 741-746.

265. Orvisky E, Drake SK, Hortin GL, et al. Enrichment of low molecular weight

fraction of serum for MS analysis of peptides associated with hepatocellular

carcinoma. Proteomics 2006; 6: 2895-2902.

266. Theodorescu D, Wittke S, Ross MM, et al. Discovery and validation of new

protein biomarkers for urothelial cancer: a prospective analysis. Lancet

Oncology 2006; 7: 230-240.

267. Jones RL. Fibrinopeptide A in diabetes mellitus. Relation to levels of blood

glucose, fibrinogen disappearance and hemodynamic changes. Diabetes 1985;

34: 836-843.

209

268. Ceriello A, Giacomello R, Stel G, et al. Hyperglycemia may determine

fibrinopeptide A plasma level increase in humans. Metabolism 1989; 38: 1162-

1163.

269. Nomura F, Takahashi N, Inami N, et al. Identification of novel and

downregulated biomarkers for alcoholism by surface enhanced laser

desorption/ionization-mass spectrometry. Proteomics 2004; 4: 1187-1194.

270. Villanueva J, Philip J, Chaparro CA, et al. Differential exoprotease activities

confer tumor-specific serum peptidome patterns. J Clin Invest 2006; 116: 271-

284.

271. Meigs JB, D'Agostino RB, Wilso OW, et al. Risk variable clustering in the

insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997;

46: 1594-1600.

272. Tessari P, Kiwanuka R, Barazzoni M, et al. Diabetic nephropathy is associated

with increased albumin and fibrinogen production in patients with type 2

diabetes. Diabetologia 2006; 49: 1955-1961.

273. Le DS, Miles R, Savage PJ, et al. The association of plasma fibrinogen

concentration with diabetic microvascular complications in young adults with

early-onset of type 2 diabetes. Diabetes Res Clin Pract 2008; 82: 317-323.

274. Lengyel Z, et al. Urinary albumin excretion is correlated to fibrinogen levels and

protein S activity in patients with type 1 diabetes mellitus without overt diabetic

nephropathy. Wien Klein Wochenschr 2004; 116: 240-245.

275. Harmanci A, Kandemir N, Dagdelen S, et al. Thrombin-activatable fibrinolysis

inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for

normal fibrinolytic state. J Diabetes Complicat 2006; 20: 40-44.

276. Ward DG, Suggett N, Cheng Y, et al. Identification of serum biomarkers for

colon cancer by proteomic analysis. Br J Cancer 2006; 94: 1898-1905.

277. Lee IN, Chen CH, Sheu JC, et al. Identification of complement C3a as a

candidate biomarker in human chronic hepatitis C and HCV-related

hepatocellular carcinoma using a proteomics approach. Proteomics 2006; 6:

2865-2873.

278. Miguet L, Bogumil R, Decloquement P, et al. Discovery and identification of

potential biomarkers in a prospective study of chronic lymphoid malignancies

using SELDI-TOF-MS. J Proteome Res 2006; 5: 2258-2269.

210